Gynecologic oncologyJournal Article
06 May 2025
Approximately 25 % of endometrial cancers harbor deficiencies in mismatch repair (dMMR). The clinical impact of this molecular aberration remains undefined in patients with high intermediate risk (HIR) endometrial cancer.
We conducted a retrospective chart review of women diagnosed with Stage I high-intermediate risk endometrioid endometrial cancer in two hospital systems in Southern California between 2016 and 2018. We collected demographic information, mismatch repair status, pathology reports, and time to recurrence.
244 patients met inclusion criteria, of which 86 (35 %) were found to be dMMR. The dMMR patient population had higher relative risks of lymphovascular space invasion (relative risk 1.63, 95 % confidence interval 1.26-2.10, p-value 0.0002) but were less likely to have deep myometrial invasion (relative risk 0.81, 95 % confidence interval 0.66-0.99, p-value 0.047) when compared to the pMMR EC cohort. No differences were found in the rate of recurrence or time to recurrence based on MMR status.
In this large, multi-institution, cohort study there were no significant differences identified between Stage I HIR dMMR and pMMR endometrioid endometrial cancer populations with regards to recurrence rates or alternate cancer-related outcomes.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
More resources:
Share: